Researchers are combining experience in chemical synthesis and nanoparticle engineering with their knowledge of cancer development to design future therapies.
Researchers uncover a key mechanism that regulates PD-L1, a protein that helps tumors evade the immune system and is the target of several immunotherapy drugs.